Bone drugs reduce metastases in breast cancer
Adjunct bisphosphonate therapy reduces the risk of bone metastases in women with early breast cancer, an updated Cochrane Review shows.
Australian researchers analysed 17 studies with 26,000 women and found that compared with placebo or no bisphosphonates, the bone agents improved survival.
The benefit was confined to postmenopausal patients.
Among women with advanced breast cancer, but no bone metastases, the drugs had no benefit. However, only three moderate-quality studies with 330 women were